lanabecestat

Lanabecestat is an orally administered small molecule inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), also known as β-secretase, and to a lesser extent BACE2. By inhibiting BACE1, lanabecestat blocks the cleavage of amyloid precursor protein (APP) at the β-secretase site, thereby reducing the production of amyloid-beta (Aβ) peptides that aggregate into plaques in the brains of patients with Alzheimer's disease. The drug was co-developed by AstraZeneca and Eli Lilly as a potential disease-modifying therapy for early and mild Alzheimer's disease. Despite robust reductions in Aβ levels in plasma and cerebrospinal fluid observed during clinical trials, phase 3 studies were terminated after interim analyses indicated that lanabecestat did not slow cognitive or functional decline compared to placebo[1][4][5][7].

Other names

lanabecestat